News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Multidisciplinary Management of Locoregional Non–Small Cell Lung Cancer

EP. 1: Mediastinal Staging in Non–Small Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 2: PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 3: Durvalumab in Stage III NSCLC Based on Performance Status

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 4: Treating for Stage III NSCLC After Progression on Durvalumab

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 5: Varied Timing of IO Therapy in Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 6: ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 7: Molecular testing in Patients With Metastatic NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 8: Integrating Perioperative Immunotherapy Strategies in NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

EP. 9: Multidisciplinary Management of Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Trending on OncLive

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA